Allspring Global Investments Holdings LLC Buys 287,322 Shares of QIAGEN N.V. $QGEN

Key Points

• Allspring Global Investments Holdings LLC has increased its stake in QIAGEN N.V. by 11.7%, now holding approximately 1.23% of the company valued at $131.76 million after purchasing 287,322 shares.
• Wall Street analysts have mixed ratings for QIAGEN, with price targets ranging from $48 to $53, while the overall consensus rating is a "Hold".
• QIAGEN reported earnings of $0.60 EPS for its latest quarter, meeting analyst expectations, with revenue increasing by 7.7% year-over-year.

Allspring Global Investments Holdings LLC increased its stake in QIAGEN N.V. (NYSE:QGEN - Free Report) by 11.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,732,963 shares of the company's stock after purchasing an additional 287,322 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 1.23% of QIAGEN worth $131,756,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC bought a new stake in QIAGEN during the fourth quarter valued at about $202,000. GAMMA Investing LLC raised its holdings in QIAGEN by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the period. Exchange Traded Concepts LLC raised its holdings in QIAGEN by 2.3% during the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock valued at $716,000 after acquiring an additional 395 shares during the period. Bank Pictet & Cie Europe AG bought a new stake in QIAGEN during the first quarter valued at about $669,000. Finally, Blue Trust Inc. raised its holdings in QIAGEN by 30.5% during the first quarter. Blue Trust Inc. now owns 13,519 shares of the company's stock valued at $543,000 after acquiring an additional 3,157 shares during the period. 70.00% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of recent analyst reports. UBS Group raised their price target on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Weiss Ratings reissued a "hold (c+)" rating on shares of QIAGEN in a report on Wednesday, October 8th. Barclays set a $53.00 price target on QIAGEN and gave the company an "overweight" rating in a report on Thursday, October 2nd. Wall Street Zen cut QIAGEN from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Cowen reaffirmed a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $49.40.

QIAGEN Stock Performance

QGEN opened at $46.93 on Monday. The firm has a market cap of $10.43 billion, a P/E ratio of 27.73, a P/E/G ratio of 2.46 and a beta of 0.66. QIAGEN N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The stock has a 50-day moving average of $47.11 and a 200 day moving average of $45.58.

QIAGEN (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting the consensus estimate of $0.60. The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The firm's revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the business posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, research analysts forecast that QIAGEN N.V. will post 2.26 EPS for the current year.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.